2019/07/22 by Lili Zhang, Chen Chen, Marvin SH Mak +7
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Alzheimer's disease research and treatments #Metabolomics and Mass Spectrometry Studies #Neuroscience and Neuropharmacology Research
paper · doi:10.1002/med.21624
openalex publication_date 2019/07/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disease. In the past decades, numbers of promising drug candidates showed significant anti-AD effects in preclinical studies but failed in clinical trials. One of the major reasons might be the limitation of appropriate animal models for evaluating anti-AD drugs. More than 95% of AD cases are sporadic AD (sAD). However, the anti-AD drug candidates were mainly tested in the familial AD (fAD) animal models. The diversity between the sAD and fAD might lead to a high failure rate during the development of anti-AD drugs. Therefore, an ideal sAD animal model is urgently needed for the development of anti-AD drugs. Here, we summarized the available sAD animal models, including their methodology, pathologic features, and potential underlying mechanisms. The limitations of these sAD animal models and future trends in the field were also discussed.